SCHEMBL4175378

SCHEMBL4175378

Cc1nc(C(N)=O)c(C2CC2)s1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 6/20 0.35
SOAT1 P35610 3/20 0.35
FAAH O00519 1/20 0.34
CHRM2 P08172 1/20 0.34
DGAT2 Q96PD7 1/20 0.34
PDE10A Q9Y233 1/20 0.34
HDAC3 O15379 6/20 0.34
HDAC1 Q13547 6/20 0.34
HDAC6 Q9UBN7 6/20 0.34
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
HSD17B10 Q99714 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HDAC4 P56524 1/20 0.32
EEF2K O00418 2/20 0.32
HSD11B1 P28845 1/20 0.32
FABP4 P15090 1/20 0.31
FABP5 Q01469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2405564 0.85 L3MBTL1 (0.38) HDAC3HDAC1HDAC6ALDH1A1GAA
SCHEMBL26684213 0.81 PIP5K1C (0.32) HDAC3HDAC1HDAC6HDAC4EEF2K
SCHEMBL7264803 0.80 EEF2K (0.30) EEF2K
SCHEMBL28301041 0.80 GFER (0.38) HDAC3HDAC1HDAC6ALDH1A1GAA
SCHEMBL2305832 0.74 PPARD (0.35) ALDH1A1GAA
SCHEMBL21066362 0.73 RAB9A (0.35) DGAT1SOAT1FAAHCHRM2DGAT2
Hydrochloric Acid SCHEMBL5013627 0.72 PPARD (0.34) ALDH1A1
SCHEMBL12661719 0.72 PDPK1 (0.38) ALDH1A1GAAHTTHSD17B10
SCHEMBL17481205 0.71 PDE10A (0.36) PDE10AHTT
SCHEMBL30536122 0.71 F2 (0.38) ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023217906-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2023-11-16 WO disclosed
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRM1, GRIN1, GRM2 DGAT1 2299/4885SOAT1 2650/4885FAAH 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.